Skip to main
MGTX
MGTX logo

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings PLC is positioned favorably due to its advancements in applying genetic medicine to both rare and more prevalent diseases, thereby addressing significant unmet medical needs across multiple therapeutic areas. The company recently reported promising data from its first-in-human study of AAV-AIPL1, indicating a potential breakthrough in treating AIPL1-associated LCA4, which bodes well for investor sentiment and market potential. Additionally, a slight reduction in R&D expenses, down to $33.5 million from $34.9 million year-over-year, reflects efficient capital management amidst ongoing innovation efforts.

Bears say

MeiraGTx Holdings PLC faces significant risks in its pipeline development, particularly regarding regulatory approvals that are critical for product commercialization. Despite potential positive clinical results, any failure to secure regulatory approval would lead to downward revisions in projected financial outcomes. Additionally, if regulatory pathways become more complex or time-consuming than anticipated, this could further adversely affect the company's financial projections and overall market valuation.

MGTX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Buy based on their latest research and market trends.

According to 2 analysts, MGTX has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.